Key result
Caucasian adults show ~37% higher rivaroxaban clearance than Asian adults, suggesting lower Asian dosing needs.
Why the study?
Whether a lower dose of rivaroxaban is required for Asians remains debatable, prompting an evaluation of potential ethnic differences in pharmacokinetic and pharmacodynamic characteristics between Asians and Caucasians.
Does rivaroxaban have different pharmacokinetic/pharmacodynamic characteristics in Asians compared to Caucasians?
Systematic Review
Does rivaroxaban have different pharmacokinetic/pharmacodynamic characteristics in Asians compared to Caucasians?
A lower dose of rivaroxaban might be required for Asians due to a 31-43% lower apparent clearance compared to Caucasians.
Answers are grounded in this paper and cite their sources.
Ethnic differences in rivaroxaban clearance suggest dosing caution in Asians; leaves open confirmation via dedicated outcome trials.
Rivaroxaban has been widely used to prevent and treat various thromboembolic diseases for more than a decade. However, whether a lower dose of rivaroxaban is required for Asians is still debatable. This review aimed to explore the potential ethnic difference in pharmacokinetic/pharmacodynamic (PK/PD) characteristics between Asians and Caucasians. A systematic search was conducted and twenty-four studies were identified, of which 10 were conducted on Asian adults, 11 on predominantly Caucasian adults, and 3 on Caucasian pediatrics. The apparent clearance (CL/F) of rivaroxaban in Caucasian adults with non-valvular atrial fibrillation (6.45–7.64 L/h) was about 31–43% higher than that in Asians (4.46–5.98 L/h) taking 10~20 mg rivaroxaban every 24 h. Moreover, there was no obvious difference in CL/F among Japanese, Chinese, Thai, and Irani people. Regarding PK/PD relationship, prothrombin time was linked to rivaroxaban concentration in a linear or near-linear manner, and Factor Xa activity was linked with the Emax model. The exposure–response relationship was comparable between Asians and Caucasians. Renal function has a significant influence on CL/F, and no covariate was recognized for exposure–response relationship. In conclusion, a lower dose of rivaroxaban might be required for Asians, and further studies are warranted to verify this ethnic difference to facilitate optimal dosing regimens.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2023) conducted a systematic review in Non-valvular atrial fibrillation. Rivaroxaban vs. Caucasians was evaluated on Apparent clearance (CL/F) of rivaroxaban (31-43% higher in Caucasians). The apparent clearance of rivaroxaban was 31-43% higher in Caucasian adults compared to Asian adults, suggesting that a lower dose of rivaroxaban might be required for Asian patients.
Synapse has enriched 10 related papers. Consider them for comparative context: